Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable or Metastatic Melanoma
Progressive Brain Metastasis

Interventions

DRUG: HBI-8000 in combination with nivolumab
DRUG: Placebo in combination with nivolumab

Sponsor

HUYABIO International, LLC.

Collaborators

[object Object]